Abstract A simple, rapid liquid chromatography-tandem mass spectrometry method was developed to identify and quantitate in human urine the isoprostanes iPF 2a -III, 15-epiiPF 2a -III, iPF 2a -VI, and 8,12-iso-iPF 2a -VI along with the prostaglandin PGF 2a and 2,3-dinor-iPF 2a -III, a metabolite of iPF 2a -III. Assay specificity, linearity, precision, and accuracy met the required criteria for most analytes. The urine sample storage stability and standard solution stability were also tested.
of smokers than nonsmokers has been reported. Maternal cigarette smoking increased F 2 -isoprostanes in umbilical vessels (22) . Vitamin C supplementation decreased iPF 2a -III in plasma from smokers (23) and nonsmokers exposed to environmental tobacco smoke (24) . Plasma, serum, and urinary levels of iPF 2a -III decreased significantly after quitting cigarette smoking (25, 26) and increased after restarting smoking (27) .
Reilly et al. (28) also reported that urinary iPF 2a -III was increased in healthy cigarette smokers, but upon cessation, levels failed to decline to those observed in nonsmokers. They also found vitamin C alone or combined with vitamin E depressed the excretion of iPF 2a -III in smokers' urine. A recent study investigating biomarkers of harm in smokers and nonsmokers found that nonsmokers had significantly reduced urinary iPF 2a -III compared with smokers (29) . On the other hand, some studies with small, targeted populations have revealed no significant differences in urinary iPF 2a -III levels in smokers and nonsmokers (30) (31) (32) . Overall, however, most studies show some relationship, with increased levels of isoprostanes associated with smoking. Recent deliberations by several work groups that focused on tobacco-related health issues considered isoprostanes promising in evaluating potential reduced-exposure tobacco products (33) .
All of the research cited above is focused mainly on the extensively studied isomer iPF 2a -III. Lately, a few studies have focused on other isoprostanes. One study reported iPF 2a -III along with its metabolite, 2,3-dinor-8-iso-prostaglandin F 2a (2,3-dinor-iPF 2a -III), to be significantly higher in smokers compared with nonsmokers (34) . Another isomer, iPF 2a -VI, was found to be increased in the urine of cigarette smokers along with iPF 2a -III (35) . Much work remains to evaluate the effect of smoking on the generation of individual isoprostane isomers.
Two primary analytical approaches have been adopted for isoprostane measurements: immunological methods and mass spectrometry. Immunological approaches include ELISA (36) and RIA (37, 38) , which are relatively inexpensive and easy to perform. These methods are considered to give only a semiquantitative estimation of isoprostane levels, because cross-reactivity is significant (36, 39) . GC-MS has a low limit of detection; however, it usually requires at least one extraction step (sorbents used include C18, silica, aminopropyl NH 2 , or immunoaffinity) and one purification step (thin-layer chromatography or liquid chromatography). GC-MS also requires derivatization of the analytes, which complicates the analysis by adding more time and potential loss of target compounds (30, (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) . As such, it is not considered a high-throughput approach.
Liquid chromatography-mass spectrometry (LC-MS) is an attractive alternative to GC-MS, because it has comparable sensitivity and derivatization is not necessary. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) with electrospray ionization (ESI) has been used successfully to separate four classes of F 2 -isoprostanes and to quantitate or semiquantitate eight isomers (53) . Taylor et al. (54) reported a validated method to separate and determine several type III isoprostanes and arachidonic acid in plasma by LC-MS/MS. Liang et al. (34) quantified iPF 2a -III and 2,3-dinor-iPF 2a -III with a total HPLC run time of 9.5 min. The method showed potential for the routine determination of urinary iPF 2a -III and 2,3-dinor-iPF 2a -III in clinical samples. Several applications of iPF 2a -III quantitation by LC-MS were reported to evaluate the role of oxidative stress in different diseases (31, 32, (55) (56) (57) . Recently, F 2 -isoprostane regioisomers and diastereomers formed in vitro were separated and identified by LC-MS (58) .
Although isoprostanes occur in various biological fluids, a urine assay is attractive because it is noninvasive, minimizes subject discomfort, requires little expertise to collect the specimen, and thus may be more suitable for large clinical trials. Plus, it circumvents the problem of artifactual generation of isoprostanes compared with plasma or other lipid-containing tissue or fluid (59, 60) .
The goal of our work was to develop a simple, accurate, and fast method for the determination of isoprostanes in human urine by LC-MS/MS to permit high-throughput sample analysis. The isomers selected for study were based on commercially available standards and include iPF 2a -III, 8,12-iso-iPF 2a -VI, 15-epi-iPF 2a -III, PGF 2a , iPF 2a -VI, and 2,3-dinor-iPF 2a -III, a major metabolite of iPF 2a -III (structures shown in Fig. 1 ). These compounds have been identified in human urine, and some have been characterized based on their biological activity (11, 61) . The prostaglandin PGF 2a is an isomer of iPF 2a -III and was included in this assay even though it is not an isoprostane. The method described here was validated according to Food and Drug Administration Center for Drug Evaluation and Research (FDA/CDER) guidelines (62) . The method was applied in a study of 24 h urine samples from smokers and nonsmokers on controlled diets. Results from smokers and nonsmokers were compared along with the degree of smoking as determined by total nicotine uptake. iPF 2a -III, 15-epi-iPF 2a -III, iPF 2a -VI, 8,12-iso-iPF 2a -VI, PGF 2a ,  2,3-dinor-iPF 2a -III, and iPF 2a -III-d 4 were obtained from Cayman Chemicals (Ann Arbor, MI). Urea, potassium chloride, hippuric acid, ammonium chloride, anhydrous magnesium sulfate, anhydrous calcium chloride, oxalic acid, anhydrous sodium silicate, creatinine, anhydrous sodium sulfate, and pepsin were from Sigma-Aldrich (St. Louis, MO). Citric acid, anhydrous sodium dihydrogen phosphate, and glucose were from Aldrich (Milwaukee, WI). Lactic acid was obtained from Fluka (Lausanne, Switzerland). High-purity water from a Milli-Q A10 Synthesis purification system (Millipore, Bedford, MA) was used for all solutions. Highpurity acetonitrile, methanol, and hexane were obtained from Burdick and Jackson (Muskegon, MI). Ammonium hydroxide (NH 4 OH) and sodium chloride were obtained from Acros Organics (Fair Lawn, NJ), and hydrochloric acid (HCl) was obtained from Fisher Scientific (Fair Lawn, NJ). Urine samples from 24 h collections were portioned into 50 ml plastic (modified polystyrene) centrifuge tubes (Corning, Corning, NY) and stored at 280jC until analysis. After thawing, 2 ml was divided into aliquots on deep 96-well plates (Phenomenex, Torrance, CA). Centrifugation of samples was done on an IEC Centra-GP8R centrifuge (Needham Heights, MA). Oasis: HLB and MAX 96-well extraction plates (10 and 30 mg) were from Waters (Milford, MA). Extraction was performed on a Phenomenex 96-well plate manifold with a customized insert to adapt shallow 0.5 ml 96-well plates (Agilent Technologies, Palo Alto, CA) for collection.
MATERIALS AND METHODS

Materials
Sample preparation
For each sample, 2 ml of urine was fortified with 50 ml of iPF 2a -III-d 4 internal standard solution (20 ng/ml) to a concentration of 500 pg/ml. It was then acidified to approximately pH 3 by the addition of 40 ml of 1 N HCl and centrifuged (3,500 rpm for 10 min at 4jC) to remove suspended material. The supernatant was loaded into a well on an HLB 96-well extraction plate (10 mg), which had been preconditioned with 1 ml of methanol and equilibrated with 1 ml of water. The plate was washed successively with 0.5 ml of 0.1 N HCl, 0.5 ml of 5:95 methanol-water, and 0.1 ml of hexane. Then, analytes and internal standard were eluted into the sample collection plate with two aliquots of 80 ml of methanol containing 0.5% NH 4 OH. After adding 100 ml of water to the eluent, the sample plate was transferred to the autosampler tray.
Standards preparation
Primary standards of individual analytes were prepared separately. Primary standards of iPF 2a -III in methanol were prepared by accurately weighing ?1 mg of iPF 2a -III into 100 ml of methanol (10 mg/ml). The other primary standards were prepared by transferring small volumes of stock solution to appropriate volumes of methanol. Resulting concentrations were 10, 25, 25, 25, and 12.5 mg/ml for 15-epi-iPF 2a -III, iPF 2a -VI, 8,12-iso-iPF 2a -VI, 2,3-dinor-iPF 2a -III, and PGF 2a , respectively. Primary standards were diluted to four working solutions by 80:20 water-methanol to prepare solutions for fortifying synthetic urine to be used for calibration standards and quality control (QC) samples. A solution of iPF 2a -III-d 4 was prepared at 20 ng/ml by transferring 10 ml of iPF 2a -III-d 4 stock (100 mg/ml) solution into 50 ml of 80:20 water-methanol for spiking standards and samples.
Calibration standards were prepared in 2 ml aliquots of synthetic urine. The formula for synthetic urine was adapted from a published reference with minor changes (63) . Yellow food color was not added, because the cosmetic appearance was not required. Instead of nitric acid, NH 4 OH was added to adjust the synthetic urine to approximately pH 6. It was then divided into aliquots in 50 ml plastic centrifuge tubes and stored at 220jC until use. Six standards were prepared in the range 30-2,000 pg/ml for iPF 2a -III and 15-epi-iPF 2a -III, 30-10,000 pg/ml for iPF 2a -VI, 8,12-iso-iPF 2a -VI, and 2,3-dinor-iPF 2a -III, and 30-5,000 pg/ml for PGF 2a . An additional standard as a blank containing only internal standard was also prepared. QC samples were prepared at the limit of quantitation (LOQ), 50%, and 95% of the calibration range, by spiking the synthetic urine with working solutions independently prepared from those used to make the calibration standards. A 50 ml aliquot of internal standard (iPF 2a -III-d 4 at 20 ng/ml) was added to each standard and QC sample, yielding a concentration of 500 pg/ml. The standards and QC samples were extracted and prepared the same as the urine samples described above. 
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Analysis of the prepared samples and standards was accomplished using an Agilent 1100 LC system (Palo Alto, CA) connected to a Micromass Quattro Ultima triple-stage mass spectrometer (Manchester, UK). Both systems were controlled using Micromass MassLynx software. The LC method used a 150 3 3 mm (5 mm) Phenomenex Luna C18(2) column preceded by a 4 3 2 mm guard column. The mobile phase consisted of A (0.15% NH 4 OH in water) and B (0.15% NH 4 OH in 95:5 acetonitrilemethanol) with a gradient of 6% B at 0 min to 21% B at 17 min (total run time of 20 min). The flow rate was 1 ml/min, with 10% of the column effluent introduced into an electrospray interface operated in the negative ion mode. The interface used nitrogen desolvation gas at 650-700 l/h and 400jC. The instrument was operated in the multiple reaction monitoring (MRM) mode, and the MRM transitions monitored are shown in Table 1 . The collision cell pressure was 2.25 3 10 23 mBar (610%). Quantitation was done using Micromass QuanLynx software. For the optimization of cone voltages and collision energies during method development, a solution of each analyte was infused into the ESI source at 5 ml/min using a syringe pump (Pump 11; Harvard Apparatus, Holliston, MA). Product ion (daughter ion) mass spectra were recorded using the continuum averaging mode of operation.
Urine sample collection
Samples from a urine mutagenicity study were analyzed with our method. In that study, 32 smokers and 12 nonsmokers were recruited. There were 16 male smokers, 16 female smokers, 6 male nonsmokers, and 6 female nonsmokers. The mean ages of smokers and nonsmokers were equivalent (44 6 9 and 44 6 7 years, respectively). Two consecutive 24 h urine samples were collected at 1 week after subjects were placed on a controlled lowmutagen diet (grilled, fried, or other heavily pyrolyzed foods eliminated, plus other restrictions). The study protocols were approved by an internal human resources review committee, and all subjects gave informed consent after learning the details of the study. Urine creatinine measurements and ELISA determination of iPF2a-III were done by Covance (Harrogate, UK). Nicotine and nine of its metabolites in urine were determined for these samples using a modification of a published method (64) .
Statistical analysis
Statistical analysis of the data was performed using logtransformed two-way ANOVA on smokers versus nonsmokers and female versus male subjects. Linear regression analysis with correlation coefficients (r) and P values for significance of slope were used to assess the effects of total nicotine uptake on each analyte. P , 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Mass spectrometry of analytes
Weakly acidic isoprostane isomers (Pk a ? 5) can be deprotonated to form (M-H) 2 precursor ions in the ESI source and detected in the negative ion mode. MS/MS can be used to fragment the precursor ions and form specific product ions. One analyte from each class of isomers was selected for optimization of mass spectrometry parameters such as cone voltage and collision energy. iPF 2a -III, 8,12-iso-iPF 2a -VI, and 2,3-dinor-iPF 2a -III were chosen as representative analytes for class III, VI, and the dinor metabolite, respectively. Optimum cone voltages were chosen from the apex of the plot of (M-H) 2 intensity against the cone voltage. For example, the (M-H) 2 intensity of iPF 2a -III maximized at a capillary voltage of 2.9 kV. The collision-induced dissociation (CID) mass spectra of (M-H) (53, 65) . Class VI analytes also have the m/z 193 fragment, but only at 10% of m/z 115 intensity in the spectra. To avoid interference, it is important that no class VI analytes coelute with class III analytes in the chromatogram. MRM was used to monitor the different classes of isoprostanes to improve specificity. The collision energy for the CID was chosen where the selected product ion had a maximum intensity. The optimized MS conditions and MRM transitions are summarized in Table 1 . The CID transition m/z 357 Y 197 was selected for the internal standard iPF 2a -III-d 4 .
Chromatography of isoprostanes
Buffer additives in the mobile phase affect not only the separation of analytes but also the sensitivity of detection. The ESI process is favored when analytes are highly ionized by the time they reach the interface. By infusing 1 mg/ml iPF 2a -III in different buffer solutions, we found that the intensity of ESI response was higher in NH 4 OH buffer solutions than in ammonium acetate (2-20 mM). At a concentration of 0.15% NH 4 OH, no ion suppression was observed (tested by infusing iPF 2a -III with 0.05, 0.1, (Fig. 3) . The MRM transition m/z 353 Y 151 for class V isomers was recorded according to a literature report (53) , although no identification of the class V isomers was done in that study because of lack of standards. A porous graphite carbon column was also tried for the separation based on one literature report (57) . However, in our experience, the column efficiency degraded after ,10 injections of urine sample extracts. This column is such a strong reverse stationary phase that it retains any hydrophobic compounds passing through the column. Some compounds did not elute easily (or at all), and the column required regeneration with tetrahydrofuran with strong acid (trifluoroacetic acid) or base (triethyl amine). This column was abandoned, because it was not suitable for our purpose (high sample throughput).
Sample preparation and extraction
A 96-well solid phase extraction plate with 10 mg of sorbent per well was used for the extraction of analytes from human urine. This plate enabled the preparation of 84 samples simultaneously along with the calibration standards and QC samples. This format also permitted the automation of sample preparation by liquid-handling instruments. Both Waters Oasis: HLB (10 mg) and MAX (10 mg) sorbents were investigated. In the extraction procedure using the MAX plate, 2 ml of urine was basified by adding 40 ml of 10% NH 4 OH and then loaded into the plate well. Each well was washed with 0.5% NH 4 OH in water and either plain methanol or methanol with 0.5% NH 4 OH. The analytes were eluted with 2% formic acid in methanol. Although MAX is supposedly more selective for acidic compounds, the recovery for iPF 2a -III was only about half that of the HLB plate, and this approach (MAX) was abandoned. The third wash step of HLB sorbent extraction procedure used 0.1 ml of hexane, as reported in other C18 sorbent methods (31, 34, 35, 49) . In our study, this washing step did not result in significant loss of analytes, and considering that it might help to clean up the sample, this step was retained in the extraction procedure.
Validation results
The internal standard was monitored by the transition m/z 357 Y 197, and no coeluting interferences were observed from the synthetic urine or authentic urines. In addition to the primary MRM transition monitored, a secondary MRM transition was monitored for each analyte ( Table 1) . Ratios of the two transitions for each analyte in three standards of spiked synthetic urine, three standards of spiked aqueous mobile phase samples, and six authentic 2 ions. Experimental conditions for iPF 2a -III were as follows: electrospray ionization (ESI) negative mode; capillary voltage, 3.0 kV; cone voltage, 43 V; collision energy, 23 eV; desolvation gas at 600 l/h and 280jC; 1 mg/ml infused to mass spectrometer with a flow rate of 5 ml/min. Experimental conditions for 2,3-dinoriPF 2a -III were as follows: ESI negative mode; capillary voltage, 2.9 kV; cone voltage, 39 V; collision energy, 12 eV; desolvation gas at 700 l/h and 400jC; 2 mg/ml infused to mass spectrometer with a flow rate of 5 ml/min. Experimental conditions for 8,12-iso-iPF 2a -VI were as follows: cone voltage, 45 V; collision energy, 22 eV; others were as for 2,3-dinor-iPF 2a -III.
Quantitation of isoprostanes in urine by LC-MS/MS
urine samples were monitored. Figure 4 shows the mean transition ratio for each analyte in different matrices. A Student's t-test for significance (66) showed that the mean transition ratio was not significantly different in either synthetic or authentic urine from that in the mobile phase for any of the analytes. Thus, the assay was specific for all six analytes in urine by this measure; however, the iPF 2a -VI isomer was not supplied in sufficient purity to enable adequate quantitation. The iPF 2a -VI standard was actually a mixture of iPF 2a -VI and another isomer (likely 5-epi-iPF 2a -VI), with two peaks observed in the chromatogram. Thus, complete validation was not extended to iPF 2a -VI. Therefore, the method is not considered valid for that analyte, although quantitative data are supplied for iPF 2a -VI in this report.
The linearity of the assay was assessed using a series of six calibration standards independently prepared as described above. The calibration range covers 30 to 2,000 pg/ml for iPF 2a -III and 15-epi-iPF 2a -III, 30 to 10,000 pg/ml for 2,3-dinor-iPF 2a -III and 8,12-iso-iPF 2a -VI, and 30 to 5,000 pg/ml for PGF 2a . All calibration plots were linear with 1/X weighting for the regression. At least five of six nonzero standards met the criteria that the calculated concentration for each standard must be 615% of the prepared concentration (620% at the LOQ) and the relative standard deviation (RSD) must be ,15% (,20% at the LOQ). Correlation coefficients were .0.99. LOQ for the method was set at 30 pg/ml for all six analytes and tested. Accuracy at LOQ was 620% of the predicted concentration with RSD , 20% (n 5 6). The raw peak-to-peak signal-to-noise ratio ranged from 10 to 40 for the six analytes in synthetic urinespiked samples at LOQ. LOQ was the lowest standard on the calibration curve.
Intrabatch accuracy and precision were assessed on three separate batches of synthetic urine spiked with the analytes at LOQ, 50%, and 95% of the calibrated range. For the mean of six replicates at each level, agreement of 615% of the prepared and measured concentrations was obtained, with RSD , 15% for the five analytes (iPF 2a -III, 15-epi-iPF 2a -III, 8,12-iso-iPF 2a -VI, PGF 2a , and 2,3-dinoriPF 2a -III) in each batch. Interbatch accuracy and precision were assessed on the mean concentrations from three batches as summarized in Table 2 . The means at each concentration were 615% of the prepared concentration, with RSD , 15% for the three batches.
Stability was tested on two sets of triplicate samples: 1) synthetic urine samples spiked at LOQ, 50%, and 95% of the calibration range; and 2) authentic urine samples from two subjects, one with endogenous analytes at relatively high levels and one with endogenous analytes at relatively low levels. For freeze-thaw stability, triplicate sam- Fig. 4 . MRM transition ratios in different matrices. SUS, three synthetic urine samples spiked at low-, medium-, and high-level standards; AU, six authentic urine samples from six subjects; MP, three mobile phase samples spiked at low-, medium-, and highlevel standards. Error bars represent one standard deviation unit. 4 OH in 95:5 acetonitrile-methanol; gradient, 6% B at 0 min to 21% B at 17 min; total run time, 20 min; flow rate, 1 ml/min with 100 ml/min introduced to the mass spectrometer; injection volume, 40 ml. Mass spectrometric parameters were as follows: ESI in negative mode; capillary voltage, 2.9 kV; desolvation gas, 700 l/h at 400jC; collision cell pressure, 2.25 3 10 23 mBar (610%); for CID transitions, cone voltage, and collision energy, see Table 1. ples at each concentration for synthetic urine samples and authentic urine samples were subjected to three complete freeze-thaw cycles with freezing at 220jC and thawing at room temperature. Short-term stability was tested by freezing and thawing at room temperature and allowing the samples to remain at room temperature for 24 h. Longterm stability was tested on triplicate samples at each concentration for synthetic urine samples and authentic urines samples by freezing them for 6 weeks before thawing and analyzing the samples. The spiked synthetic urine samples were 615% of the prepared concentration (620% at LOQ). The endogenous analytes in authentic urine samples were 615% of the fresh concentration after freeze-thaw, short-term, and long-term storage. Autosampler storage stability was assessed on the two sets of samples mentioned above with three duplicates by reanalyzing them after remaining in the autosampler tray for 2 days at room temperature. Variation was ,15% for all spiked synthetic urine samples and unspiked authentic urine samples. Primary standards were found to be stable for up to 6 weeks at 4jC. Diluted solutions (working solutions) were found to be stable for up to 6 weeks in the dark at room temperature. In addition, freshly prepared and 7 week old iPF 2a -III-d 4 spiking solutions (10 ng/ml) were monitored in the same batch of runs. Comparison of peak areas showed no significant decomposition to d 3 , d 2 , d 1 , and d 0 through hydrogen/deuterium exchange after 7 weeks.
To test the dilution effect, seven synthetic urine samples were spiked at three times the upper LOQ, which is 6,000 pg/ml for iPF 2a -III and 15-epi-iPF 2a -III, 30,000 pg/ml for 8,12-iso-iPF 2a -VI and 2,3-dinor-iPF 2a -III, and 15,000 pg/ml for PGF 2a . The samples were then diluted 4-fold with distilled deionized water and prepared and analyzed as the other samples. The measured amounts multiplied by 4 were 615% of the prepared amounts, with RSD < 8% for all analytes, showing no significant effect of 4-fold dilution.
Most reported methods for isoprostane quantitation have used calibration curves generated from standards prepared in mobile phase (or aqueous buffer). Although this avoids interference of the endogenous analytes present in the authentic urine, which results in a high constant (y intercept) in the regression equation, the FDA/CDER guidelines recommend that calibration standards be prepared in the same matrix as the samples. While using authentic urine to prepare calibration standards, the concentration of endogenous analytes can be calculated from the regression equation of the calibration curve (32, 39) . In our method, synthetic urine was selected for the preparation of standards because it is easily manufactured in the laboratory from commercially available chemicals, is readily prepared as needed, and also avoids interferences from endogenous analytes. In addition, synthetic urine composition is constant compared with that of authentic urine, which is more variable from one subject to another. A recovery experiment was carried out to test the suitability of the synthetic urine matrix for standard preparation. Two milliliter aliquots of authentic urine were spiked at 0, low (2-103 LOQ), 25%, and 50% of calibration range levels and measured against standards prepared in synthetic urine. Basal concentrations in the authentic urine samples were determined from the unspiked samples. The acceptance criterion is that the percentage recovery of the spiked concentration should be within 85-115% (80-120% at LOQ). Based on the recovery results (Table 3) , synthetic urine was accepted as a suitable matrix for iPF 2a -III, 15-epiiPF 2a -III, 8,12-iso-iPF 2a -VI, and PGF 2a but was borderline for 2,3-dinor-iPF 2a -III. For the latter analyte, ,80% was recovered when spiked into authentic urine. However, by LOQ, limit of quantitation; RSD, relative standard deviation. % Delta represents the percentage difference of the measured concentration and the prepared concentration. 50%M and 95%M represent 50% and 95% of the maximum calibration level, respectively. Spiked concentration of analytes in authentic urine calculated based on a calibration curve prepared in synthetic urine. 25%M and 50%M represent 25% and 50% of the maximum calibration level, respectively. simply diluting the urine sample 6-fold with water or increasing HLB extraction sorbent from 10 to 30 mg without changing any other sample preparation procedure, the recovery for 2,3-dinor-iPF 2a -III was improved to an acceptable range. The likely reason for the low recovery of 2,3-dinor-iPF 2a -III was overloading of the 10 mg solid phase extraction well. Ion suppression variation may also play a role in the reduced recovery for 2,3-dinor-iPF 2a -III, because it elutes several minutes before the internal standard.
Comparison of LC-MS/MS and ELISA
Results for iPF 2a -III obtained by this LC-MS/MS method were compared with results from an ELISA determination and found to be significantly correlated (r 5 0.890, P , 0.0001); however, an ?2-fold higher concentration bias was observed for the ELISA data (Fig. 5) . We hypothesize that the difference was attributable to cross-reactivity in ELISA in which more than one isoprostane isomer responded. The LC-MS/MS method described here demonstrates specificity for the single isomer iPF 2a -III and is likely more representative of the true concentration.
Results for human urine
Our method was applied to a set of 24 h urine samples. The six analytes were determined in two 24 h urine samples from 32 smokers and 12 age-and sex-matched nonsmokers using the LC-MS/MS method. From the measured concentration of each analyte, adjusted measurements were calculated, including mass per milligram of creatinine and total mass per day ( Table 4 ). The latter units are possible because 24 h urine samples were collected; moreover, they may be more indicative of total oxidative stress.
The mean values of iPF 2a -III were 513 6 275 and 294 6 104 pg/mg creatinine in smokers and nonsmokers, respectively. These results are consistent with results in the literature using an LC-MS/MS method with a reverse phase column (34) . The mean concentrations of 2,3-dinoriPF 2a -III (3,030 6 1,546 and 2,046 6 836 pg/mg creatinine in smokers and nonsmokers, respectively) were slightly lower than the results in the same study.
As shown in Table 4 , excretion of iPF 2a -III and 2,3-dinor-iPF 2a -III was significantly higher (except for output per day of 2,3-dinor-iPF 2a -III, which was marginally significant at P 5 0.06) in smokers than in nonsmokers in units of both pg/mg creatinine and mg/day. The same trend was observed when male subjects and female subjects were compared separately in units of pg/mg creatinine. The increase of the total output per day was not statistically significant for iPF 2a -III and 2,3-dinor-iPF 2a -III (except for iPF 2a -III in the female group) when the male and female groups were compared separately. The concentration of iPF 2a -VI in units of mg/mg creatinine and mg/day tended to be higher in smokers than in nonsmokers but did not reach statistical significance. The average excretion of 15-epi-iPF 2a -III, 8,12-iso-iPF 2a -VI, and PGF 2a was not different between smokers and nonsmokers in units of mg/mg creatinine or mg/day. The mean level of all isoprostanes analyzed (iPF 2a -III, 2,3-dinor-iPF 2a -III, 15-epi-iPF 2a -III, 8,12-iso-iPF 2a -VI, and iPF 2a -VI) was significantly higher in women than in men in units of pg/mg creatinine but not in units of mg/day. The same difference was observed in both smokers and nonsmokers, and these results are consistent with iPF 2a -III and 2,3-dinor-iPF 2a -III values (pg/mg creatinine) reported in the literature (55, 67) . iPF 2a -III in plasma was also reported to be significantly higher in women than in men (24) . The reason for the higher level of isoprostanes in women was not clear, although greater susceptibility to lipid oxidation in female smokers is a possibility (55) . Interestingly, in our study, the total excretion per day of analytes was not different by gender. Investigation of the clinical conditions associated with systemic oxidative stress showed that smoking, gender, age, body mass index, glucose, total cholesterol, and history of cardiovascular disease are all factors that can affect the excretion of iPF 2a -III (67) . Note that the sample size in our study was limited and only gender and smoking status were considered. It is possible that other factors not considered here may have affected our results. Also, a limitation of this study is that the number of nonsmokers included was far less than the number of smokers.
One potential mechanism of increased oxidative stress associated with cigarette smoking is the direct actions of various oxidants and preoxidants present in tobacco smoke (68) . Obata et al. (19) found that the duration of smoking and the number of cigarettes per day were not correlated with urine isoprostane concentration. Reilly et al. (28) found that urinary cotinine was higher in heavy smokers and tended to correlate with urinary iPF 2a -III, but this difference did not attain statistical significance. Tsikas et al. (30) showed a weak linear correlation between creatinine-corrected urinary iPF 2a -III level and number of cigarettes reportedly smoked. To investigate the relationship between isoprostane excretion and cigarette smoke exposure, concentrations of urinary nicotine and nine nicotine metabolites (cotinine, cotinine-N-glucuronide, nicotine-N-glucuronide, trans-3 ¶-hydroxycotinine, trans-3 ¶- hydroxycotinine-O -glucuronide, cotinine-N-oxide, nicotine-N-oxide, norcotinine, and nornicotine) were measured by LC-MS/MS. The results are presented as nicotine equivalents, which is the molar sum of nicotine and each metabolite. Determination of total nicotine equivalents is considered a good estimate of total exposure to cigarette smoke (69) (70) (71) . The linear regression of isoprostane excretion against the total nicotine equivalent excretion in the smokers' group revealed that only iPF 2a -VI and 8,12-iso-iPF 2a -VI had significant correlations (although very weak) with nicotine uptake (Table 5) . In all cases for daily excretion, the linear correlation between isoprostanes and nicotine uptake was weak, with r < 0.18-0.40, indicating that factors other than nicotine uptake affect isoprostane excretion.
In this set of samples, the mean excretion of 2,3-dinoriPF 2a -III was approximately six times higher than that of iPF 2a -III. The correlation between 2,3-dinor-iPF 2a -III and its parent compound iPF 2a -III was significant (r 5 0.7619, P , 0.0001). This observation is consistent with the literature findings that iPF 2a -III together with its metabolite 2,3-dinor-iPF 2a -III might provide an integrated index of iPF 2a -III formation and lipid oxidation in vivo (34, 72) .
Although the number of subjects in this study was limited, it is interesting that some isoprostanes seem to be more increased than others in smokers. Metabolic stability may play a role in the observed levels of isoprostanes. For example, perhaps all isoprostanes are increased equally by any source of oxidative stress (e.g., smoking) but some are more efficiently metabolized, so that their determined concentrations appear less affected by variations in oxidant levels. Such an event would make highly metabolized isoprostanes appear to be less correlated with smoking than less metabolized isoprostanes. Another possibility is that exposure to different types of oxidants may affect the mechanisms that create isoprostanes and thereby affect their distribution. Perhaps further research will provide clues to what is occurring with exposure to smoke.
In conclusion, an LC-MS/MS method was developed and validated to quantitate iPF 2a -III, 15-epi-iPF 2a -III, iPF 2a -VI, and 8,12-iso-iPF 2a -VI along with prostaglandin PGF 2a and the metabolite 2,3-dinor-iPF 2a -III in human urine. This method can be helpful for high-throughput measurement of isoprostanes for investigation of the pathophysiological role of lipid peroxidation in associated human diseases. The data reported here support literature reports that iPF 2a -III and its metabolite 2,3-dinor-iPF 2a -III are increased slightly in smokers. Among smokers, the total output of isoprostanes iPF 2a -VI and 8,12-iso-iPF 2a -VI shows a slight positive correlation with the amount of exposure to tobacco smoke (nicotine uptake). As there are numerous isoprostane isomers formed in the body, it may be possible that others not determined in this study are more correlated with cigarette smoking and will provide a useful tool for monitoring this form of oxidative stress.
